Reclast (Zoledronic Acid) Manufacturing, Supply & Shortage History

What Reclast (Zoledronic Acid) Is and Who Makes It

Reclast is a third-generation nitrogen-containing bisphosphonate delivered as a 5 mg intravenous infusion over at least 15 minutes. Novartis holds the branded Reclast license in the United States. The active pharmaceutical ingredient (API), zoledronic acid, is also sold under the brand name Zometa at 4 mg for oncologic indications such as bone metastases and hypercalcemia of malignancy, which matters for supply because the two formulations share manufacturing infrastructure.

Generic versions of the 5 mg/100 mL infusion entered the US market after patent expiration in 2013. Manufacturers now include Mylan (now Viatris), Fresenius Kabi, Hikma Pharmaceuticals, and Sun Pharmaceutical, among others. The API is synthesized primarily at facilities in India and China, with finished-dose manufacturing concentrated in Europe and India. That geographic concentration is one reason supply disruptions tend to cluster rather than resolve quickly.

How the Drug Is Manufactured

Zoledronic acid is a synthetic compound built around an imidazole ring attached to a bisphosphonate backbone. The imidazole nitrogen atoms give it roughly 10,000 times greater potency than the first-generation bisphosphonate etidronate at inhibiting osteoclast function, because nitrogen-containing bisphosphonates target the mevalonate pathway enzyme farnesyl pyrophosphate synthase (FPPS) directly, rather than producing a toxic ATP analog.

Manufacturing involves multi-step organic synthesis of the API, followed by sterile filtration, aseptic fill-finish into 100 mL IV bags or vials, and extensive quality-control testing for endotoxins, particulate matter, and pH stability. The sterile fill-finish step is the most capacity-constrained part of the supply chain globally, and it is the stage at which most quality-related recalls and shortage triggers originate.

The Oncology-Osteoporosis Overlap Problem

The 4 mg Zometa formulation and the 5 mg Reclast formulation share the same API and much of the same manufacturing footprint. When oncology demand for Zometa rises, or when a shared fill-finish facility has a compliance issue, both products are affected simultaneously. This dual-market dependency is a structural supply vulnerability that has never been fully resolved.

How Reclast Works: Mechanism at the Cellular Level

Reclast works by suppressing osteoclast-mediated bone resorption. After IV administration, the drug is rapidly cleared from plasma and adsorbed onto hydroxyapatite crystals on bone surfaces, concentrating at sites of active bone turnover.

Inhibition of the Mevalonate Pathway

Once inside an osteoclast, zoledronic acid inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. Blocking FPPS prevents the prenylation of small GTPase signaling proteins (Ras, Rho, Rac). Without functional prenylated GTPases, osteoclasts lose their ruffled border, cytoskeletal integrity, and ability to secrete acid and proteases onto bone. The osteoclast undergoes apoptosis.

Why Annual Dosing Works

Zoledronic acid has an exceptionally long skeletal half-life, estimated at more than 10 years in humans, because it remains embedded in bone mineral until that bone segment is remodeled. A single 5 mg infusion provides sustained suppression of bone turnover markers for 12 months or longer, which is what makes once-yearly dosing both effective and, critically for supply-disruption scenarios, somewhat flexible in timing.

Sex-Specific Pharmacology

Women have higher baseline bone turnover rates than men at equivalent ages, and postmenopausal women experience a further acceleration of resorption due to estrogen withdrawal. The anti-resorptive effect of zoledronic acid is therefore proportionally greater in postmenopausal women than in men at the same dose. The HORIZON-PFT trial enrolled 7,736 postmenopausal women with osteoporosis and demonstrated a 70% relative risk reduction in morphometric vertebral fractures (3.3% vs 10.9% over 36 months) with annual 5 mg infusions. Hip fracture risk fell by 41% and non-vertebral fracture risk by 25% in that same trial.

Supply and Shortage History: A Timeline

The US supply of zoledronic acid has been punctuated by at least three distinct shortage periods since 2013. Understanding the causes helps you and your clinician plan ahead.

2013-2016: Generic Entry and Market Fragmentation

When Novartis's US patent on Reclast expired in 2013, multiple generic manufacturers entered the market rapidly. Initial generic availability actually improved supply and reduced cost. However, market fragmentation meant that each individual manufacturer held smaller production volumes, and any single facility's quality failure could remove a meaningful share of national supply without a backup immediately available.

2017-2019: Quality-Related Shortage

The most documented pre-pandemic shortage occurred between approximately 2017 and 2019. The FDA drug shortages database listed zoledronic acid injection as in shortage, with the stated reason being manufacturing delays. At least one generic manufacturer received FDA warning letters related to sterile manufacturing practices at its fill-finish facility during this period, reducing available lots. Novartis Reclast remained nominally available but at significantly higher out-of-pocket cost for patients whose pharmacy benefit did not cover the brand when generics were listed as the preferred alternative.

Clinicians at infusion centers reported in this period that appointment wait times for zoledronic acid infusions stretched from weeks to months. For postmenopausal women with high fracture risk, this created real clinical uncertainty about whether to switch to an oral bisphosphonate, delay, or pay out of pocket for Reclast.

2020-2021: Pandemic-Era Disruption

The COVID-19 pandemic affected nearly all IV drug supply chains. Zoledronic acid was not among the most severely affected products in 2020, but infusion center closures and staffing shortages created access barriers that functioned as a de facto shortage for many patients. Women who had been scheduled for annual infusions in spring 2020 frequently had appointments canceled with no clear rescheduling timeline.

2022-2023: The Most Recent Shortage

The FDA drug shortage database again listed zoledronic acid injection in shortage during 2022 and into 2023, driven by a combination of API sourcing delays from overseas suppliers and increased demand as patients who had deferred treatment during the pandemic returned to care. Fresenius Kabi, one of the larger US generic suppliers, reported intermittent supply interruptions. Pharmacies and infusion centers in some regions reported allocation limits, meaning they could only obtain a fraction of their normal order quantities.

During this period, the American Society for Bone and Mineral Research (ASBMR) and individual osteoporosis specialists publicly addressed the question of infusion delays, noting that the long skeletal half-life of zoledronic acid provides a buffer against fracture risk when infusions are delayed by a few months.

What a Shortage Means for Your Fracture Risk

This is the question that matters most if you are a postmenopausal woman on annual zoledronic acid infusions and your appointment has been pushed back.

The Evidence on Delayed Dosing

A practical clinical framework for managing zoledronic acid delays, drawn from published pharmacokinetic data and real-world cohort evidence, has emerged from the post-pandemic literature. The key points are as follows.

Bone turnover markers, specifically serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide), remain suppressed for well beyond 12 months after a single infusion in most women. A 2015 analysis published in the Journal of Bone and Mineral Research showed that CTX remained below pre-treatment baseline for 18-24 months in approximately 60% of women who received a single dose. This suppression window is the pharmacological basis for tolerating a delayed re-dose.

Clinically, most osteoporosis specialists accept a re-dosing window of 12-18 months for women who are at moderate fracture risk and who had at least 2-3 years of prior zoledronic acid therapy. For women who are in their first or second year of treatment, or who have had a recent fragility fracture, a delay beyond 2-3 months is harder to justify, and switching to a daily or weekly oral bisphosphonate (alendronate or risedronate) as a bridge is reasonable.

When a Bridge Therapy Makes Sense

If your infusion is expected to be delayed by more than 3 months and you fall into any of these categories, ask your clinician about bridge therapy:

• You had a fragility fracture within the past 24 months
• Your bone mineral density (BMD) T-score is below -3.0 at any site
• You are on glucocorticoids at a dose of 7.5 mg prednisone equivalent or more per day
• You are in your first year of zoledronic acid treatment after stopping denosumab (where rebound resorption is a real risk)

Alendronate 70 mg weekly is the most commonly used bridge because it is widely available, inexpensive, and has decades of fracture-reduction data in postmenopausal women. Risedronate 150 mg monthly is an alternative for women who cannot tolerate alendronate.

Pregnancy, Lactation, and Contraception: What You Must Know

Zoledronic acid is contraindicated in pregnancy. This is not a precautionary soft warning. Bisphosphonates cross the placenta and incorporate into fetal bone, and animal studies with zoledronic acid showed maternal and fetal toxicity including reduced fetal body weight, delayed ossification, and post-implantation loss at doses lower than the human therapeutic dose.

Pregnancy Category and Human Data

Zoledronic acid carries FDA pregnancy category D, meaning there is positive evidence of human fetal risk, or the drug is contraindicated on the basis of animal data combined with theoretical harm. The human data on inadvertent exposure during pregnancy is limited to case reports. A 2011 systematic review of bisphosphonate exposure in pregnancy found no consistent pattern of major malformations in the small number of documented human cases, but the authors specifically noted that data were too sparse to draw reassuring conclusions, and zoledronic acid was among the least-studied agents.

Because of the drug's extraordinarily long skeletal half-life (potentially more than a decade), bisphosphonate stored in maternal bone can theoretically be released into the bloodstream during a subsequent pregnancy, even years after the last infusion, and cross the placenta. The ACOG Committee Opinion on bone health in pregnancy recommends against bisphosphonate use in women who are pregnant or planning pregnancy in the near future.

Contraception Requirements

If you are a woman of reproductive age receiving zoledronic acid for premenopausal osteoporosis, glucocorticoid-induced osteoporosis, or osteogenesis imperfecta, you must use reliable contraception throughout treatment and for an undefined period afterward because of the drug's persistence in bone. There is no FDA-specified washout period before attempting conception, which is itself a source of clinical anxiety. The guidance from most reproductive endocrinologists and maternal-fetal medicine specialists is to discuss the risks explicitly and to delay conception for at least 12 months after the last infusion if at all possible, recognizing that the theoretical fetal risk from bone-stored drug persists longer than that.

Lactation

Data on zoledronic acid transfer into human breast milk are absent. Animal studies suggest transfer does occur. Given the drug's mechanism and persistence, most clinicians advise against breastfeeding in women who require treatment, though the clinical scenario of a breastfeeding woman who urgently needs zoledronic acid is uncommon. The National Institutes of Health LactMed database notes that oral absorption of bisphosphonates is extremely low, and any drug excreted into milk would likely have minimal systemic absorption in the infant, but this reasoning is theoretical rather than empirically tested for zoledronic acid specifically.

Premenopausal Women: A Special Caution

Premenopausal women with secondary osteoporosis represent a growing clinical population receiving zoledronic acid, including women with anorexia nervosa-related bone loss, long-term glucocorticoid use, or cancer treatment-induced bone loss. If you are premenopausal and your clinician recommends zoledronic acid, a pregnancy-prevention discussion is mandatory before the first infusion, and you should be offered long-acting reversible contraception (LARC) if you are sexually active with a partner capable of causing pregnancy.

Life-Stage Guide: Who This Drug Is Right For, and Who It Is Not

Postmenopausal Women (the Primary Population)

Zoledronic acid is most studied and most commonly used in postmenopausal women. The HORIZON-PFT trial enrolled women between 65 and 89 years old with a T-score of -2.5 or below, or with -1.5 or below plus radiographic vertebral fracture. The 70% vertebral fracture reduction and 41% hip fracture reduction from this trial are the numbers that define the drug's clinical standing.

Postmenopausal women who are good candidates include those who:

• Cannot tolerate or absorb oral bisphosphonates due to esophageal disease, bariatric surgery, or poor adherence
• Prefer a once-yearly administration schedule over daily or weekly oral dosing
• Have a T-score below -2.5 or a prior fragility fracture
• Are transitioning off denosumab (where zoledronic acid is the preferred agent to prevent rebound resorption)

Perimenopause

Perimenopausal women are rarely primary candidates for zoledronic acid unless they have additional risk factors. Bone loss accelerates in the 2-3 years before the final menstrual period, but absolute fracture risk in most women in their late 40s remains low enough that pharmacotherapy is not yet indicated. Menopausal hormone therapy (MHT) preserves bone density in perimenopause and is usually the preferred first-line approach in this life stage for women who have menopausal symptoms alongside bone concerns. If a perimenopausal woman has T-score below -2.5 or a fragility fracture, however, zoledronic acid is appropriate regardless of menopausal status, with mandatory contraception.

Younger Premenopausal Women

Premenopausal use is off-label for most indications but occurs clinically. The ACOG guidance on low bone density in reproductive-age women cautions against routine use of bisphosphonates in women who may become pregnant, given the long skeletal half-life. Situations where it is used include glucocorticoid-induced osteoporosis when benefit clearly outweighs risk, and cancer-treatment-related bone loss in women whose fertility plans are complete.

Women Who Should Not Use Zoledronic Acid

• Pregnant women (contraindicated, see above)
• Women planning pregnancy in the near future
• Women with creatinine clearance below 35 mL/min (renal impairment significantly impairs drug clearance and increases toxicity risk; the FDA label contraindicates use below this threshold)
• Women with hypocalcemia (must be corrected before infusion; calcium and vitamin D supplementation are required)
• Women with a documented hypersensitivity to bisphosphonates

Managing a Supply Disruption: A Practical Checklist

If your annual Reclast infusion cannot be scheduled on time, here is how to work through the decision with your clinician.

Step 1. Quantify your delay. Less than 3 months: wait and reschedule, no action needed for most women. 3-6 months: assess your fracture risk. More than 6 months: consider bridge therapy.

Step 2. Know your fracture risk category. Your clinician can calculate a FRAX score using your BMD and clinical risk factors. A 10-year major osteoporotic fracture probability above 20% (or hip fracture above 3%) is the US treatment threshold under the National Osteoporosis Foundation guidelines, and women above this threshold have more at stake in a supply disruption.

Step 3. Ask about alternatives. If zoledronic acid is unavailable for more than 6 months and your fracture risk is high:

• Alendronate 70 mg weekly (oral, widely available, well-studied in postmenopausal women)
• Denosumab 60 mg subcutaneously every 6 months (Prolia; different mechanism, not a bisphosphonate, requires strict adherence to prevent rebound resorption if stopped)
• Ibandronate 150 mg monthly oral or 3 mg IV quarterly (less fracture data than alendronate or zoledronic acid at the hip)

Step 4. Check the FDA shortage database directly. It is publicly searchable by drug name. If zoledronic acid is listed, the entry will name which manufacturers are affected and what the projected resolution date is. Knowing whether one manufacturer is affected or all of them changes your options.

Step 5. Contact your infusion center, not just your prescriber. Shortage allocation is managed at the pharmacy/infusion center level. Sometimes one center has stock and another does not, even within the same health system.

Evidence Gaps Specific to Women

Women have been the primary subjects of bisphosphonate trials for osteoporosis, which is one area where clinical trial representation of women is actually stronger than in many other disease categories. The HORIZON-PFT trial was conducted almost entirely in women. However, specific subgroups of women remain understudied.

Premenopausal women with secondary osteoporosis have little high-quality randomized trial data on zoledronic acid specifically. Most evidence in this group is drawn from open-label trials or extrapolated from glucocorticoid-induced osteoporosis studies that included both sexes. A 2010 ACOG Practice Bulletin on osteoporosis acknowledged this gap explicitly, noting that evidence for pharmacologic treatment of premenopausal bone loss is limited.

Women of color, including Black and Hispanic women, were underrepresented in HORIZON-PFT. This is relevant because fracture risk calculators were developed primarily in white European populations, and the absolute fracture risk in Black women with the same T-score may differ from the risk used to power those trials.

The effect of zoledronic acid in women transitioning from perimenopause to menopause, a period of rapid bone turnover acceleration, has not been studied in a dedicated trial. Dosing intervals and duration in this specific transition window are extrapolated from general postmenopausal data.